TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36287047
Drug: Positive anti-HLA
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive anti-HLA antibodies
Study: 36287047
Drug: Negative anti-HLA
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative anti-HLA antibodies
Study: 36287929
Drug: High indoxyl
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High indoxyl sulfate (IS) levels (cutoff 0.365 mg/dL)
Study: 36287929
Drug: High myostatin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High myostatin levels (cutoff 4.5 ng/mL)
Study: 36288547
Drug: Teliso-V (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily)
Study: 36288714
Drug: v-ATPase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: v-ATPase inhibitors (e.g., etidronate)
Study: 36288714
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of etidronate
Study: 36288758
Drug: Stereotactic Ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic Ablative Radiotherapy (SAbR) with a median prescribed dose of 45 Gy (range, 35-55) in 5 daily fractions to tumor and 40 Gy (35-45) to nodes.
Study: 36289094
Drug: Lenvatinib 20
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 20 mg/day plus Pembrolizumab 200 mg every 3 weeks
Study: 36291912
Drug: MEMMAT-like metronomic
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEMMAT-like metronomic antiangiogenic approach including daily oral thalidomide, fenofibrate, celecoxib, alternating 21-day cycles of low-dose oral etoposide and cyclophosphamide, IV bevacizumab, and intraventricular therapy with alternating etoposide and liposomal cytarabine.
Study: 36294516
Drug: Invasive endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive endovascular treatment for CVS
Study: 36295001
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) transfusion (single unit with anti-RBD IgG concentration > 5 AU/mL)
Study: 36301137
Drug: Pembrolizumab (PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (PD-1 inhibitor)
Study: 36301604
Drug: Mindfulness training
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness training via a smartphone app (10 weekly sessions, daily practice)
Study: 36301928
Drug: Dissolved tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolved tablet of EVG/COBI/FTC/TAF
Study: 36301928
Drug: Whole tablet
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole tablet of EVG/COBI/FTC/TAF
Study: 36302175
Drug: Guadecitabine (subcutaneously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine (subcutaneously, 45 mg/m2/day for 5 consecutive days, planned 28-day cycle)
Study: 36302562
Drug: Ivuxolimab (0.1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivuxolimab (0.1-3 mg/kg every 2 weeks) + utomilumab (20 or 100 mg every 4 weeks)
Study: 36302562
Drug: Ivuxolimab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivuxolimab (30 mg every 2 weeks) + utomilumab (20 mg every 4 weeks)
Study: 36302579
Drug: Weekly physical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly physical education (PE) and recess minutes in 2020
Study: 36302584
Drug: Baseline eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline eGFR <45 mL/min/1.73 m²
Study: 36302584
Drug: Baseline eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline eGFR 45-60 mL/min/1.73 m²
Study: 36302584
Drug: Baseline eGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline eGFR >60 mL/min/1.73 m²
Study: 36303108
Drug: Regional citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional citrate anticoagulation with continuous infusion of 8% trisodium citrate into the arterial line and supplementation of 1 M calcium chloride into the venous line
Study: 36303228
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg IV on day 8 of a 21-day cycle), low-dose cyclophosphamide (50 mg orally twice daily for 1 week on and 1 week off), and G100 (20 µg intra-tumoral injection weekly for at least 6 weeks, maximum 12 weeks)
Study: 36303228
Drug: G100 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: G100 (20 µg intra-tumoral injection weekly)
Study: 36303332
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy program
Study: 36304240
Drug: Preventive measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive measures (e.g., social distancing, mask usage)
Study: 36304457
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg/kg every 3 weeks for ≤35 cycles
Study: 36305957
Drug: Ipatasertib 400
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib 400 mg once-daily orally
Study: 36306154
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group maintaining daily activities.
Study: 36306158
Drug: Training Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training Intervention and Program of Support (TIPS) consisting of a 1-month training intervention with self-paced learning modules and a webinar, followed by an 11-month support program including monthly site meetings and access to a virtual community of practice.
Study: 36307410
Drug: Ad-sig-hMUC1/ecdCD40L adenoviral-vector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad-sig-hMUC1/ecdCD40L adenoviral-vector vaccine
Study: 36307775
Drug: SCT200 (anti-EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT200 (anti-EGFR monoclonal antibody) administered intravenously every 3 weeks at doses ranging from 0.5-15.0 mg/kg.
Study: 36307826
Drug: Eribulin, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin, administered for a median of 4.5 cycles (1-23 cycles), with a median overall survival of 12 months.
Study: 36307845
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) 15 Gy/1 fraction after SBRT 40 Gy/5 fractions
Study: 36308640
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 100 mg CBD:100 mg THC
Study: 36309488
Drug: High-intensity inspiratory
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity inspiratory muscle training (IMT) at home, 80% of max, daily in Phase 1 and 2, once weekly in Phase 3, self-selected frequency in Phase 4, with one weekly supervised session except Phase 4
Study: 36309837
Drug: Epacadostat (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat (300 mg) plus durvalumab
Study: 36309981
Drug: Venetoclax (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (100, 200, or 400 mg daily for 14 days every 28-day cycle) + Azacitidine (75 mg/m² on Days 1-7 every cycle)
Study: 36310395
Drug: Qualitative interviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative interviews with unvaccinated ED patients regarding COVID-19 vaccination concerns and potential approaches to increase vaccine acceptance.
Study: 36310566
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) with feeding modifications
Study: 36310566
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) alone
Study: 36313145
Drug: Orelabrutinib 150
Normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orelabrutinib 150 mg orally daily until disease progression or unacceptable toxicity
Study: 36314160
Drug: POC whole-blood
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: POC whole-blood hs-cTnI assay (Atellica VTLi) with a threshold of <4 ng/L
Study: 36314198
Drug: Cannabis inhalation
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis inhalation
Study: 36314999
Drug: First Booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: First Booster of SARS-COV-2 mRNA Vaccine
Study: 36315224
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS text message reminders to follow their chosen anchoring plan (messages group; treatment group 1)
Study: 36315224
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS text messages and incentives conditional on taking their ART medication around the time of their chosen anchor (incentives group; treatment group 2)
Study: 36316061
Drug: INCAGN01949 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCAGN01949 monotherapy (7-1400 mg) in 14-day cycles
Study: 36316628
Drug: Oral L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-citrulline (150 mg/kg)
Study: 36316733
Drug: FPG value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG value (≥ 92 mg/dl) following Italian Diabetes Societies recommendations for COVID 19 pandemic period
Study: 36317254
Drug: Regenerative peripheral
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative peripheral nerve interfaces and intramuscular electrodes
Study: 36318387
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg (qw or q2w)
Study: 36318494
Drug: Bifactor solution
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifactor solution of DSM-XC
Study: 36318879
Drug: Intravenous dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose of 40 IU of vasopressin with epinephrine
Study: 36319569
Drug: Treatment dissatisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment dissatisfaction (PAC-QOL)
Study: 36319717
Drug: Intratumoral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratumoral administration of CV8102
Study: 36319717
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of i.t. CV8102 with systemic anti-PD-1 treatment
Study: 36319944
Drug: STOPP/START-based in-hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOPP/START-based in-hospital medication review
Study: 36320022
Drug: Stimulant medication
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant medication for ADHD
Study: 36322113
Drug: MindShift CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MindShift CBT app plus treatment as usual (TAU) over 6 days
Study: 36322714
Drug: Bone marrow-derived,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow-derived, allogeneic MSCs (75 million MSCs administered via direct injection, with repeat injection at 3 months if needed)
Study: 36322714
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MSC therapy)
Study: 36322782
Drug: 4-week mobile
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week mobile health (mHealth) prescription to monitor for AF recurrences
Study: 36322825
Drug: Dasatinib/prednisone induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib/prednisone induction followed by blinatumomab/dasatinib postremission therapy for 3 cycles and dasatinib/prednisone maintenance.
Study: 36322825
Drug: Blinatumomab reinduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab reinduction therapy for patients not achieving response by day 56.
Study: 36322825
Drug: Central nervous
Normalized name: CENTRAL NERVOUS SYSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central nervous system prophylaxis with intrathecal methotrexate for a total of 8 doses.
Study: 36323235
Drug: BMS-963272 (MGAT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-963272 (MGAT2 inhibitor)
Study: 36323235
Drug: Selective DGAT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective DGAT1 inhibitor
Study: 36323435
Drug: Nivolumab (anti-PD-1)
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) combination therapy
Study: 36323435
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4
Study: 36323444
Drug: Dapagliflozin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin with standard therapy
Study: 36323464
Drug: Maternal antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibiotic treatment during pregnancy
Study: 36323612
Drug: Afatinib (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (first-line treatment)
Study: 36324098
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor (AR) CAG repeats
Study: 36324191
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for trigger finger
Study: 36325355
Drug: FCR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCR treatment (fludarabine-cyclophosphamide-rituximab)
Study: 36325389
Drug: KIO-100 (PP-001),
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIO-100 (PP-001), a small molecule DHODH-inhibitor
Study: 36326731
Drug: Immunotherapy (IO)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IO)
Study: 36326731
Drug: Non-immunotherapy systemic
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-immunotherapy systemic anticancer therapies (non-IO)
Study: 36327378
Drug: Family-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Based Treatment delivered by videoconferencing (FBT-V)
Study: 36328033
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus FOLFOX (intravenous trastuzumab-pkrb at 6 mg/kg on day 1, FOLFOX regimen with intravenous oxaliplatin [85 mg/m2])
Study: 36328377
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks for up to 2 years or until progression, toxicity, or protocol-specified discontinuation.
Study: 36328399
Drug: Three-dose primary
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose primary SARS-CoV-2 vaccination in patients with IMID
Study: 36328399
Drug: Two-dose primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose primary SARS-CoV-2 vaccination in healthy controls
Study: 36328399
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of vaccination
Study: 36328399
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of antibody decline rates
Study: 36328851
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone and case management services
Study: 36328851
Drug: Baseline daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline daily alcohol consumption
Study: 36330013
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (including drug-coated balloon, directional atherectomy, supera, and drug-eluting stent)
Study: 36330140
Drug: Whole-grain wheat
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain wheat (WGW) intervention (98 g/d)
Study: 36330484
Drug: Buparlisib, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib, an oral pan-PI3K inhibitor, administered for a median of 4.5 months (range 2-33).
Study: 36330484
Drug: Buparlisib, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib, an oral pan-PI3K inhibitor.
Study: 36330490
Drug: Apatinib 500
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg
Study: 36330490
Drug: Apatinib 750
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 750 mg
Study: 36330490
Drug: Apatinib 850
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 850 mg
Study: 36330525
Drug: Arginase-1 peptide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginase-1 peptide vaccine (three 20-mer peptides from the ARG1 immunological 'hot spot' region with Montanide ISA-51 adjuvant, administered subcutaneously every third week, maximum 16 vaccines)
Study: 36330525
Drug: Arginase-1 peptide
Normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginase-1 peptide vaccine
Study: 36331674
Drug: Orally-administered bendamustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally-administered bendamustine hydrochloride, dosages ranging from 175 to 840 mg/m2, administered once daily for 7, 14, and 21 days every 3 weeks as one cycle.
Study: 36331676
Drug: CA102N (0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA102N (0.72 mg/kg Nim equivalent)
Study: 36331676
Drug: CA102N in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CA102N in combination with trifluridine-tipiracil
Study: 36331681
Drug: CBA in
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBA in antiarrhythmic drug (AAD)-refractory patients
Study: 36332763
Drug: Dupilumab 200
Normalized name: dupilumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 200 mg and 300 mg every 2 weeks
Study: 36332953
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral tenofovir/emtricitabine (TDF/FTC) with adherence self-management interventions (point-of-care urine drug-level assay, HIV self-testing, weekly text messaging)
Study: 36332964
Drug: IL-6 antagonist
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 antagonist therapy
Study: 36333464
Drug: Camidanlumab tesirine
Normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camidanlumab tesirine (Cami); specific dosage and duration not mentioned.
Study: 36333616
Drug: Atopic Dermatitis
Normalized name: SALICYLIC ACID 20 mg in 1 g TOPICAL CREAM [DermaD ATOPIC DERMATITIS Therapeutic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopic Dermatitis Impact Scale (ADerm-IS) Daily Activities
Study: 36333618
Drug: Spesolimab 600-mg
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 4 weeks
Study: 36333618
Drug: Spesolimab 600-mg
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 600-mg loading dose followed by 300-mg maintenance dose every 12 weeks
Study: 36333618
Drug: Spesolimab 300-mg
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab 300-mg loading dose followed by 150-mg maintenance dose every 12 weeks
Study: 36333676
Drug: Glucose control
Normalized name: Glucose Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose control treatment group
Study: 36334048
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral glutamine supplementation
Study: 36334289
Drug: MRI-guided focused
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided focused ultrasound (FUS) treatment targeting the hippocampus, frontal lobe, and parietal lobe, with 3 separate treatment sessions performed 2 weeks apart.
Study: 36334289
Drug: MRI-guided focused
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided focused ultrasound (FUS) treatment
Study: 36335079
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy from the quitline
Study: 36335079
Drug: Any pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any pharmacotherapy
Study: 36335079
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy receipt
Study: 36335079
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy use
Study: 36335217
Drug: gedatolisib (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: gedatolisib (180 mg QW) plus cisplatin
Study: 36335217
Drug: gedatolisib (90-310
Approvals — FDA: no, EMA: no, PMDA: no
Description: gedatolisib (90-310 mg QW) plus docetaxel
Study: 36335479
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide (500 mg once daily)
Study: 36335915
Drug: Apixaban (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (2.5 mg BID)
Study: 36335915
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) phenprocoumon (INR 2.0 to 3.0)